<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79121">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02148146</url>
  </required_header>
  <id_info>
    <org_study_id>105591</org_study_id>
    <nct_id>NCT02148146</nct_id>
  </id_info>
  <brief_title>Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis</brief_title>
  <official_title>Clinical Trial of Omegaven™ Therapy for Parenteral Nutrition Associated Cholestasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical study designed to evaluate the safety and benefit of a fish oil based fat
      emulsion in the treatment of liver disease associated with prolonged use of intravenous
      nutrition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims of Study

        1. To determine the safety profile of an intravenous omega-3 fat emulsion (Omegaven™)

        2. To determine if established PN associated liver disease can be reversed or its
           progression halted by using a parenteral fat emulsion prepared from fish oil as
           measured by normalization of serum levels of hepatic enzymes and bilirubin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Duration of elevated direct bilirubin</measure>
    <time_frame>Weekly until direct bilirubin below 2 mg/dL, average treatment for 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>Omegaven</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No placebo or comparator arm. Only intervention arm with Omegaven.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omegaven</intervention_name>
    <description>Fish oil emulsion given 1g/kg/day as infusion</description>
    <arm_group_label>Omegaven</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &lt; 18 years old

          2. Patients will be PN dependent (unable to meet nutritional needs solely by enteral
             nutrition) and are expected to require PN for at least another 30 days, may be
             inpatient or outpatient

          3. Patients considered eligible for study participation must have parenteral nutrition
             associated liver disease (PNALD) as defined as a direct bilirubin of 2 mg/dl or more.
             Other causes of liver disease should be excluded. A liver biopsy is not necessary for
             treatment

          4. Direct bilirubin &gt; 2.0 mg/dl

          5. Signed patient informed consent

          6. The patient must have utilized standard therapies to prevent the progression of
             his/her liver disease including surgical treatment, cyclic PN, avoiding overfeeding,
             reduction/removal of copper and manganese from PN, advancement of enteral feeding, or
             the use of ursodiol (i.e., Actigall®)

        Exclusion Criteria:

          1. Pregnancy

          2. Other causes of chronic liver disease (Hepatitis C, Cystic fibrosis, biliary atresia,
             and alpha 1 anti-trypsin deficiency)

          3. Enrollment in any other clinical trial involving an investigational agent (unless
             approved by the designated physicians on the multidisciplinary team)

          4. The parent or guardian or child unwilling to provide consent or assent

          5. Patients known to be allergic to fish or egg protein and patients with the following
             contraindications to Omegaven™ use:

               -  Impaired lipid metabolism

               -  Severe hemorrhagic disorders

               -  Unstable diabetes mellitus

               -  Collapse and shock

               -  Stroke/embolism

               -  Recent cardiac infarction

               -  Undefined coma status
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae H Kim, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jae Kim, MD PhD</last_name>
    <phone>6195433759</phone>
    <email>neojae@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Renee Bridge, RN</last_name>
    <phone>6195433759</phone>
    <email>rbridge@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8774</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Kim, MD PhD</last_name>
      <phone>619-543-3759</phone>
      <email>neojae@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Renee Bridge, RN</last_name>
      <phone>6195433759</phone>
      <email>rbridge@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jae H Kim, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital of San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Kimball, MD</last_name>
      <phone>858-966-4045</phone>
      <email>akimball@rchsd.org</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Knodel, RT</last_name>
      <phone>858-966-4045</phone>
      <email>eknodel@rchsd.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amy Kimball, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>May 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Jae H. Kim</investigator_full_name>
    <investigator_title>Associate Clinical Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>short bowel syndrome</keyword>
  <keyword>intestinal failure</keyword>
  <keyword>total parenteral nutrition associated cholestasis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
